These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28665229)

  • 21. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.
    Regitnig P; Reiner A; Dinges HP; Höfler G; Müller-Holzner E; Lax SF; Obrist P; Rudas M; Quehenberger F
    Virchows Arch; 2002 Oct; 441(4):328-34. PubMed ID: 12404057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry?
    Maleki Z; Shariat S; Mokri M; Atri M
    Arch Iran Med; 2012 Jun; 15(6):366-9. PubMed ID: 22642247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma.
    Bueno Angela SP; Viero RM; Soares CT
    Cytopathology; 2013 Feb; 24(1):26-32. PubMed ID: 22220518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    Am J Clin Pathol; 2000 Feb; 113(2):251-8. PubMed ID: 10664627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.
    Maleki S; Dorokhova O; Sunkara J; Schlesinger K; Suhrland M; Oktay MH
    Diagn Cytopathol; 2013 Oct; 41(10):864-70. PubMed ID: 23447357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing.
    Hoshino I; Imai K; Nanjo H; Nakamura R; Saito Y; Fujishima S; Saito H; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
    J Clin Pathol; 2019 Jan; 72(1):25-30. PubMed ID: 30228214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
    Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
    J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients.
    Domanski AM; Monsef N; Domanski HA; Grabau D; Fernö M
    Cytopathology; 2013 Feb; 24(1):21-5. PubMed ID: 22783929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
    Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
    Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
    Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP
    Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.